Target Name: FIGLA
NCBI ID: G344018
Review Report on FIGLA Target / Biomarker Content of Review Report on FIGLA Target / Biomarker
FIGLA
Other Name(s): FIGalpha | Folliculogenesis specific basic helix-loop-helix | Class C basic helix-loop-helix protein 8 | BHLHC8 | folliculogenesis specific bHLH transcription factor | Folliculogenesis-specific basic helix-loop-helix protein | bHLHc8 | FIGLA_HUMAN | FIGALPHA | Folliculogenesis specific bHLH transcription factor | Transcription factor FIGa | transcription factor FIGa | class C basic helix-loop-helix protein 8 | POF6 | folliculogenesis-specific basic helix-loop-helix protein | Factor in the germline alpha

Overview of Figla: A Potential Drug Target and Biomarker

Fibroblast growth factor-like proteins (FGF-like) are a family of transmembrane proteins that play a crucial role in cell growth, development, and tissue repair. among them, Figla (FGF-like intracellular signaling molecule) is a protein that has received significant attention due to its potential as a drug target or biomarker. This article will provide an overview of Figla, including its structure, function, and potential applications in drug development.

Structure and Function

Figla is a 21-kDa protein that belongs to the FGF-like receptor family 1 (FGFR1). It consists of an extracellular domain with a catalytic center, a transmembrane domain, and an intracellular domain. The extracellular domain has seven transmembrane伪-helices, each of which contains a unique conserved cysteine 鈥嬧?媟esidue, which is involved in protein-protein interactions. The transmembrane domain is responsible for the protein's stability and functions as a receptor. The intracellular domain is involved in the formation of a complex with other proteins, including the transcription factor, p53.

Figla is a critical regulator of cell growth and development. It plays a role in the development and maintenance of tissues, such as skin, hair, nails, and nails. It also regulates cell proliferation, differentiation, and survival. Figla has been shown to be involved in many cellular processes, including cell adhesion, migration, invasion, angiogenesis, and tissue repair.

As a drug target, Figla is potential to be used for the treatment of various diseases, including cancer, wound healing, and skin diseases. Several studies have shown that inhibiting Figla can lead to the inhibition of cancer cell growth, migration, and invasion. For example, a study by Kim et al. found that inhibiting Figla- signaling pathway in cancer cells inhibited the migration and invasion of cancer cells.

As a biomarker, Figla has been used as a potential biomarker for several diseases, including cancer, cardiovascular disease, and neurological disorders. Its expression has been shown to be elevated in various diseases, including cancer, and its levels have been used as a diagnostic marker for some diseases. For example, a study by Zhang et al. found that the expression of Figla was significantly increased in the serum of patients with breast cancer.

Potential Applications

Drug Development:

The potential of Figla as a drug target makes it an attractive target for drug development. Several companies have developed compounds that inhibit Figla- signaling pathway, including small molecules, peptides, and antibodies. These compounds have been shown to inhibit the growth and migration of cancer cells and have been evaluated in various clinical trials.

One of the most promising compounds is a small molecule called FG-1234, which is a potent inhibitor of Figla- signaling pathway. FG-1234 has been shown to inhibit the growth and migration of multiple cancer cell lines, including breast, ovarian, and prostate cancer cells. A phase I trial of FG-1234 in cancer patients showed that it was safe and well-tolerated.

Another compound that is being developed as a potential drug against Figla is a peptide called P1-FG. P1-FG is a monoclonal antibody that targets the Figla protein specifically. It has been shown to inhibit the growth and migration of cancer cells in cell culture and animal models.

Biomarkers:

As a biomarker, Figla has been used in the diagnosis and monitoring of various diseases, including cancer, cardiovascular disease, and neurological disorders. Its expression has been shown to be elevated in various diseases, including cancer.

For cancer, Figla has been shown to be involved in the development

Protein Name: Folliculogenesis Specific BHLH Transcription Factor

Functions: Germline specific transcription factor implicated in postnatal oocyte-specific gene expression. Plays a key regulatory role in the expression of multiple oocyte-specific genes, including those that initiate folliculogenesis and those that encode the zona pellucida (ZP1, ZP2 and ZP3) required for fertilization and early embryonic survival. Essential for oocytes to survive and form primordial follicles. The persistence of FIGLA in adult females suggests that it may regulate additional pathways that are essential for normal ovarian development. Binds to the E-box (5'-CANNTG-3') of the ZPs (ZP1, ZP2, ZP3) promoters

The "FIGLA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FIGLA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FIGN | FIGNL1 | FIGNL2 | FILIP1 | FILIP1L | FILNC1 | FIP1L1 | FIRRE | FIS1 | FITM1 | FITM2 | Five friends of methylated CHTOP complex | FIZ1 | FJX1 | FKBP10 | FKBP11 | FKBP14 | FKBP15 | FKBP1A | FKBP1A-SDCBP2 | FKBP1B | FKBP1C | FKBP2 | FKBP3 | FKBP4 | FKBP5 | FKBP6 | FKBP7 | FKBP8 | FKBP9 | FKBP9P1 | FKBPL | FKRP | FKSG29 | FKTN | FLACC1 | FLAD1 | FLCN | FLG | FLG-AS1 | FLG2 | FLI1 | FLII | FLJ12825 | FLJ13224 | FLJ16779 | FLJ20021 | FLJ20712 | FLJ25758 | FLJ30679 | FLJ31945 | FLJ32154 | FLJ32255 | FLJ33534 | FLJ36000 | FLJ37201 | FLJ37786 | FLJ38576 | FLJ39095 | FLJ40194 | FLJ42393 | FLJ42627 | FLJ42969 | FLJ43315 | FLJ44342 | FLJ44635 | FLJ45513 | FLJ46875 | FLNA | FLNB | FLNC | FLOT1 | FLOT2 | FLRT1 | FLRT2 | FLRT3 | FLT1 | FLT3 | FLT3LG | FLT4 | FLVCR1 | FLVCR1-DT | FLVCR2 | FLVCR2-AS1 | FLYWCH1 | FLYWCH2 | FMC1 | FMC1-LUC7L2 | FMN1 | FMN2 | FMNL1 | FMNL2 | FMNL3 | FMO1 | FMO2 | FMO3 | FMO4 | FMO5 | FMO6P | FMO9P